ARS Pharmaceuticals Inc SPRY
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2020-12-04 |
| Shares Out. | 99,300,000 |
| Website | ars-pharma.com/ ↗ |
| Phone | 18009279800 |
| Employees | 159 |
| Revenue | $22.7M |
| Gross Profit | $16.4M |
| Net Income | -$60.6M |
| Free Cash Flow | -$175.3M |
| Total Assets | $287.6M |
| Total Liabilities | $226.3M |
| Equity | $61.3M |
About ARS Pharmaceuticals Inc
ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the commercialization and development of neffy (currently identified in the European Union (EU) and United Kingdom (U.K.) by the trade name EURneffy and in China) for needle-free intranasal delivery of epinephrine for emergency treatment of Type I allergic reactions, including anaphylaxis. Neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows Neffy to safely provide intranasal delivery of epinephrine at a low dose within the exposures of approved injectable products across a range of dosing conditions.
ARS Pharmaceuticals Inc is a publicly traded company under the ticker symbol SPRY on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
10 analysts (2026-07-01)